{"entity":{"id":"nct06234098","kind":"trial","name":"Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of AT-1965 Liposome Injection in advanced solid tumours, run by Alyssum Therapeutics, now recruiting.","summary":"Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors is a phase 1/2 interventional study registered as NCT06234098 by Alyssum Therapeutics, with 100 participants planned, started 2024-02-13 and due to reach its primary completion in 2026-12. Interventions recorded: AT-1965 Liposome Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06234098","url":"https://clinicaltrials.gov/study/NCT06234098"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06234098","phase":"1/2","setting":"A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors","sponsor":"Alyssum Therapeutics","enrolled":100,"outcomes":[]},"route":"/trials/nct06234098/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}